ArticleJournal of thoracic disease2025
Rate of early restenosis after tracheal resection in patients post-COVID-19 infection: a multicenter real-life study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation and Comparison of Treatment with Polymerised Collagen or Pirfenidone as Stand-Alone Therapy on the Production of Profibrotic Factors in Tracheal Stenosis and Tracheal Anastomosis Scarring After Resection.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic has led to a rise in tracheal stenosis (TS) due to prolonged invasive ventilation. Limited data are available on outcomes following tracheal resection and anastomosis (TRA) in this specific population. This study aimed to evaluate early restenosis, postoperative complications, and reintervention rates after TRA in a real-world, multicenter setting. Methods: This prospective, observational study included patients who developed TS after invasive mechanical ventilation for COVID-19 and underwent tracheal or laryngotracheal resection across five high-volume thoracic surgery centers in Italy (June 2020 to December 2023). The primary endpoint was restenosis incidence; secondary endpoints included complication rates and in-hospital mortality. Results: Ninety patients (mean age: 58.4±11.5 years; 62% male) were included. Most patients (81%) developed stenosis post-tracheostomy; 35% had failed prior endoscopic treatments, while 65% underwent upfront surgery. Major and overall complication rates were 7.8% and 30%, respectively. Early restenosis (defined as restenosis occurring within 90 days from surgery) occurred in 8 patients (8.8%) at a mean of 34.2±26.0 days. Interventions included endoscopic dilatation (n=4), stenting (n=1), and tracheostomy (n=3). Multivariate analysis identified preoperative endoscopic treatment [hazard ratio (HR) 12.25, 95% confidence interval (CI): 1.45-103.2, P=0.02] and diabetes (HR 8.64, 95% CI: 1.12-66.3, P=0.03) as independent predictors of early restenosis. Conclusions: TRA in post-COVID-19 patients, when performed in high-volume centers, is safe and effective, with low restenosis and complication rates. However, early restenosis may occur, particularly in patients with comorbidities or prior endoscopic procedures. Close bronchoscopic follow-up is warranted within the first months postoperatively to enable timely detection and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.